Cancer Molecular Imaging

癌症分子成像

基本信息

批准号：
7944543
负责人：
Anna M Wu
金额：
$ 5.35万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-04-02 至 2013-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7944543
关键词：
Abnormal Cell Address Advanced Development Animal Model Animals Area Area Analyses Attention Biochemical Process Biological Biological Process Cancer Biology Cancer Center Support Grant Cancer Detection Cancer Patient Cancer Survivor Cell Communication Cell Therapy Cells Chronic Clinic Clinical Clinical Treatment Clinical Trials Collaborations Complex DRD2 gene Detection Development Diagnosis Discipline Disease Disease Progression Dopamine Effectiveness Engineering Evaluation Event Fostering Funding Gefitinib Gene Expression Genomics Gifts Glioblastoma Goals Grant Health Herpesvirus 1 Homeostasis Human Image Imaging Device Imaging technology Immune Immune response Immunotherapy Individual Inflammation Institution Investigation Jonsson Comprehensive Cancer Center of University of California Los Angeles Kinetics Label Laboratories Leadership Life Lilium Malignant Neoplasms Measurement Measures Microfluidics Modeling Molecular Molecular Probes Molecular Target Monitor National Cancer Institute Organism Patients Peer Review Physics Play Positron-Emission Tomography Pre-Clinical Model Prevention Procedures Process Proteomics Publications Radiolabeled Reporter Genes Research Personnel Resolution Resource Sharing Rodent Model Role Scientist Screening procedure Seeds Signal Transduction Syndrome System T-Lymphocyte Techniques Therapeutic Tracer Translating Translations Tumor Biology Tumor Immunity Viral analytical method analytical tool base body system cancer cell cancer imaging cancer immunotherapy cancer initiation cancer therapy cell transformation chemobrain chemotherapy clinical application cost design imaging probe improved in vivo inhibitor/antagonist innovation insight instrument instrumentation interest malignant breast neoplasm mathematical model melanoma member molecular imaging multimodality non-invasive monitor novel oncology preclinical study prevent programs radiotracer research clinical testing response restoration technology development therapeutic gene therapeutic target therapy development tool tumor initiation

项目摘要

The Cancer Molecular Imaging Program Area is composed of 18 members, spanning 7 Departments within UCLA. In the past competing cycle, investigators from this Program authored 265 publications, of which 232 (88%) were inter-programmatic and 89 (34%) intra-programmatic. 71 (27%) were placed in high-impact ournals. Nine members of this Program Area used 6 out of the 8 Shared Resources that are currently funded by the JCCC. During the current funding year, peer-reviewed funding totaled $4.4 million in total costs, including $3.8 million from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the CMI Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the CMI Program Area total $317,584. These funds supported Seed Grants, recruitment/retention & Program Area Leadership support. Four of the Program Area Members were the recipients of JCCC support. Molecular imaging is a powerful set of approaches to reveal functional changes in living subjects that has enabled compelling insights into human health and disease. The newly proposed JCCC Cancer Molecular Imaging Program Area brings together investigators with a common focus on employing molecular imaging tools to investigate cancer in living individuals, from laboratory rodent models to patients. The efforts of CMI investigators are organized around four main themes. 1) Development of instrumentation and analytical tools. Moving molecular imaging forward requires constant development and improvement in instrumentation to provide higher resolution, sensitivity, and quantitative measurement of biological molecules and processes in vivo. 2) Development of novel molecular imaging approaches. CMI Program Area members have been leaders in the field of molecular imaging, with significant contributions in novel tracers, imaging gene expression using reporter genes, developing animal models to exploit the advantages of non-invasive, repeated and quantitative imaging, and in development of multimodality imaging instrumentation and analytic procedures. These tools are employed in the study of cancer initiation and progression, metastatic spread, and response to treatment, in preclinical models. 3) Imaging immune responses and response to immunotherapy. An important focus of the CMI Program Area is to develop the tools to monitor immune responses and follow the effects of cancer immunotherapy in living individuals. 4) Translation of imaging technologies to clinical contexts for cancer patients. Ultimately, the goal of the CMI Program Area is to improve the understanding, detection, and treatment of cancer. CMI Program Area members pursue translational goals that include both determining the best use of currently available molecular tracers in the clinic (e.g., FDG-PET, FLT-PET) as well as translating new molecular tracers through clinical evaluation.

癌症分子成像程序区域由18个成员组成，跨越了7个部门加州大学洛杉矶分校。在过去的竞争周期中，该计划的调查人员撰写了265个出版物，其中232个（88％）是程序间的，89（34％）的前编程。 71（27％）被放置在高影响力中我们的名字。该计划区域的九名成员使用了当前资助的8个共享资源中的6个成员由JCCC。在当前的资金年度，同行评审的资金总计440万美元，总成本，包括来自国家癌症研究所的380万美元。与其他计划领域一样，JCCC促进了互动活动的数量和许多支持CMI研究人员的共享资源计划区域。在当前的赠款周期中，JCCC的资金以CCSG的形式开发 CMI计划区的资金，机构支持和慈善礼物总计317,584美元。这些资金支持种子赠款，招聘/保留和计划领域领导力支持。计划区域的四个成员是JCCC支持的接受者。分子成像是一种强大的方法，可以揭示具有活性受试者的功能变化使人们能够对人类健康和疾病的见解。新提出的JCCC癌症分子成像程序区域将研究人员汇集在一起，以使用分子成像为重点从实验室啮齿动物模型到患者，研究活人中的癌症的工具。 CMI的努力调查人员在四个主要主题周围组织。 1）仪器和分析的发展工具。向前移动分子成像需要持续发展和仪器的改进提供更高的分辨率，灵敏度和定量测量生物分子和过程体内。 2）开发新型分子成像方法。 CMI计划区域成员已经分子成像领域的领导者，在新型示踪剂中具有重要贡献，成像基因使用报告基因的表达，开发动物模型来利用非侵入性的优势重复和定量成像，以及多模式成像仪器和分析的开发程序。这些工具用于研究癌症的开始和进展，转移性扩散以及在临床前模型中对治疗的反应。 3）成像免疫反应和对免疫疗法。 CMI计划领域的一个重要重点是开发监控免疫的工具反应并遵循癌症免疫疗法对活人的影响。 4）成像的翻译癌症患者临床环境的技术。最终，CMI计划领域的目标是改善癌症的理解，检测和治疗。 CMI计划区成员追求翻译目标包括确定当前可用的分子示踪剂的最佳使用诊所（例如FDG-PET，FLT-PET），以及通过临床评估来翻译新的分子示踪剂。